AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191). Originally developed as an anti-obesity compound, it shows preclinical evidence for promoting fat metabolism without affecting blood sugar or growth.
Verified sources for AOD-9604
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of AOD-9604
Stimulates lipolysis and increases fat oxidation through GH-receptor-independent mechanisms, without affecting IGF-1 or glucose metabolism.
Stimulates breakdown of stored triglycerides in adipose tissue (proposed), releasing fatty acids for energy use.
Increases β3-adrenergic receptor expression in adipose tissue (proposed), enhancing sensitivity to lipolytic signals.
Does NOT bind to growth hormone receptors, and does not increase IGF-1 levels like full GH.
No adverse effects on insulin sensitivity in preclinical studies (proposed), distinct from full GH.
No effects on glucose metabolism (proposed), avoiding diabetogenic concerns of full GH.
GH receptor independent mechanism, isolating fat-burning effects without growth/anabolic effects
Read Full AOD-9604 Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Metabolic & Weight Loss
UPDATE: Retatrutide Clears First Phase 3 Diabetes Trial — 16.8% Weight Loss, 2.0% A1C Drop
Eli Lilly’s triple-agonist retatrutide delivered superior A1C and weight reductions in its first Phase 3 diabetes trial. Full TRANSCEND-T2D-1 breakdown.
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
Retatrutide Phase 3 Results: 28.7% Weight Loss and Beyond
Eli Lilly's triple-agonist retatrutide delivered record-breaking weight loss in the TRIUMPH-4 trial. Here's what the Phase 3 data means for the future of obesity treatment.
RFK Jr. Says 14 Peptides Are Coming Back: Ban Reversal
HHS Secretary RFK Jr. told Joe Rogan that ~14 peptides banned by the FDA in 2023 will return to Category 1, restoring legal compounding access.